GLP-1 medicines and supplements: Evidence-Based Supplement Guide

Nine of the 72 people in Avelor with a saved stack hold something taken alongside a GLP-1 medicine. That phrasing is the whole point of this guide. The medicine is not a supplement, its effectiveness is not what is in question, and **nothing here is a reason to change, reduce, or stop it.** The question this guide answers is narrower and more useful: given that you are taking one, what does the research say about what to eat, what to take, and what to watch. Start from what these medicines do, because the supplement questions follow from it. Systematic reviews and meta-analyses cover semaglutide for weight loss in obesity without diabetes (PMID 36578889) and compare agents against each other in type 2 diabetes (PMID 38286487). A broad mapping review assesses both effectiveness and risks across outcomes (PMID 39833406). Cardiovascular outcome evidence exists in people with obesity and established cardiovascular disease (PMID 37952131), with longer-term weight data from the same trial (PMID 38740993). Meta-analyses cover cardiovascular, mortality and kidney outcomes (PMID 31422062, 39608381). A trial extension reported what happens to weight and cardiometabolic measures after the medicine is withdrawn (PMID 35441470), which is the finding most relevant to anyone thinking of these as a short course. **The reason supplements matter here is body composition, not weight.** A review examined changes in lean body mass with these therapies and the strategies proposed to mitigate them (PMID 38937282). A systematic review and network meta-analysis assessed their effect on body composition specifically (PMID 39719170). A tirzepatide trial substudy using DXA scans reported that of the weight lost, about three quarters was fat and about one quarter was lean mass (PMID 39996356). That proportion held across sex, age and how much weight came off. The same proportion appeared in the placebo group, so that split is what rapid weight loss does, not something the medicine adds. A separate review sets out strategies for minimising muscle loss during incretin-mimetic treatment (PMID 39295512), and a review of sarcopenic obesity covers the underlying problem (PMID 40296814). The consistent theme across them is that what protects lean mass is adequate protein and resistance training, not a compound. The second reason is absorption and nutrition, and it is the one most often missed. These medicines slow gastric emptying. A review reports that retained stomach contents are found more often at upper gastrointestinal endoscopy in people taking them, though rarely with pulmonary aspiration (PMID 39418085). The same review says guidance on withholding them before a procedure is limited by thin evidence. That is why the single most important thing in this guide is to tell any anaesthetist or surgeon that you take one, well before the day (PMID 38290907). A broader review covers the gastrointestinal effects, mechanisms and management (PMID 39096914). On nutrition, a narrative review pooled six studies (PMID 41549912). It reported vitamin D deficiency in about one in thirteen users at six months and about one in seven at twelve. It also reported ferritin roughly a quarter to a third lower than in a comparator drug group, and more than six in ten users eating below requirements for calcium and iron. Its own authors say those data are mainly observational and that causality cannot be established. A joint consensus statement from three European obesity organisations covers nutritional, functional and psychological considerations (PMID 42419343). That consensus statement is the single most useful document here for anyone taking one of these medicines.

1. **Keep taking the medicine as prescribed.** Everything below is about what happens alongside it. 2. **Prioritise protein and resistance training over any supplement.** That is what the muscle-loss reviews converge on (PMID 39295512, 38937282). 3. **Read the consensus statement, or ask your clinician about it.** It was written for exactly this situation (PMID 42419343). 4. **Expect oral absorption to change and plan around it.** Slowed gastric emptying affects things taken by mouth, supplements included (PMID 39418085). 5. **Tell any clinician who is about to sedate or operate on you that you take one** (PMID 38290907). 6. **Ask about micronutrient status rather than guessing at a stack** (PMID 41549912).

Where the research supports a timeframe, the body composition substudy measured change across the treatment period of a trial running over more than a year (PMID 39996356). The withdrawal extension followed participants for about a year after stopping (PMID 35441470). The gastric emptying effect is present while the medicine is active, and a pharmacokinetic review describes how long that is for semaglutide (PMID 38952487). No duration applies to the protein and training recommendation, because it describes what to do for as long as you are losing weight.

- **Almost none of this evidence tests a supplement on top of a GLP-1 medicine.** The muscle-loss reviews describe strategies and mechanisms (PMID 39295512, 38937282). They are not randomised trials of a product added to the medicine, and this guide does not present them as though they were. - **Body composition results come from substudies and pooled analyses, not from trials designed to answer that question** (PMID 39996356, 39719170). Lean mass was rarely the primary outcome. - **The micronutrient review is narrative, not systematic** (PMID 41549912). It is the best available summary and it is a weaker design than the ones cited elsewhere in this guide. - **Hair loss evidence is early.** A systematic review of current evidence exists (PMID 41998799) alongside a call for further investigation (PMID 38741261). Neither shows that a supplement stops it happening. - **Thyroid risk evidence is observational and contested** (PMID 36356111). It is included because people ask about it, not because it is settled. - **The withdrawal data describes what happened in a trial, not what will happen to you** (PMID 35441470).

- **Do not change, reduce, skip, or stop a GLP-1 medicine because of anything in this guide.** Any change belongs to **the clinician who prescribes it**. - **Tell anaesthetists and surgeons that you take one, well before any procedure.** Retained stomach contents are found more often at endoscopy in people taking these medicines, and perioperative guidance exists, though the review is explicit that the evidence behind it is limited (PMID 38290907, 39418085). This is the caution most likely to matter and the one most often forgotten. - **Persistent vomiting, severe or ongoing abdominal pain, or an inability to keep fluids down are reasons to contact a clinician promptly**, not to add an anti-nausea supplement. The gastrointestinal effects of these medicines are documented and have a management pathway (PMID 39096914, 26177483). - **Slowed gastric emptying can change how other oral products are absorbed** (PMID 39418085). If you take any medicine by mouth where timing matters, raise it with **a pharmacist or your prescriber** rather than adjusting it yourself. - **Ask about nutrition and micronutrient status rather than self-treating a suspected deficiency** (PMID 41549912, 42419343). Eating much less makes intake matter more, and the answer is a measured one from **a clinician or dietitian**. - **Rapid weight loss with reduced intake is the setting where lean mass is lost** (PMID 40296814). If you are not able to eat enough protein or train, that is worth raising with **your clinician** rather than solving with a powder alone.

This is the best-covered condition in the product on the medicine side and one of the worst on the supplement side, which is an unusual combination worth stating plainly. **The medicine side is well covered.** Twelve entities carry the `glp1` type, including `avelor:med:semaglutide`, `avelor:med:tirzepatide`, `avelor:med:liraglutide` and `avelor:med:dulaglutide`. The interaction catalogue holds 61 rows naming one of those four drugs, every one of them carrying explanatory text. **The supplement side is where it breaks.** Those 61 rows use 19 distinct supplement keys, and 8 of them have no `supplement_compound` entity at all: potassium, magnesium, chromium picolinate, an electrolyte blend, iron, vitamin D, thiamine and calcium. That inverts the usual problem and is worth being precise about. The catalogue **knows** about iron and vitamin D alongside a GLP-1. The registry cannot produce either as a supplement entity. So the two halves of the check are keyed on different vocabularies, and the half a user's typed input passes through is the half that cannot name the row waiting for it. Supplements named in this guide that do resolve and carry a catalogue key: - `avelor:sup:protein`, `avelor:sup:whey-protein` - `avelor:sup:creatine` - `avelor:sup:electrolytes` - `avelor:sup:cyanocobalamin` Resolves but has no catalogue key, so it displays as recognised and is checked against nothing: - `avelor:sup:multivitamin` Vitamin D's absence blocks the join for the fourth guide running, after bloodsugar, immune and pcos. Iron's absence blocks it for the second, after adhd. Both are named in catalogue rows for these medicines, which makes their absence from the registry the narrowest and most fixable gap found in any guide so far.

| PMID | Title | | --- | --- | | 36578889 | "Efficacy and Safety of Semaglutide for Weight Loss in Obesity Without Diabetes: A Systematic Review and Meta-Analysis" | | 38286487 | "Comparative effectiveness of GLP-1 receptor agonists on glycaemic control, body weight, and lipid profile for type 2 diabetes: systematic review and network meta-analysis" | | 39833406 | "Mapping the effectiveness and risks of GLP-1 receptor agonists" | | 37952131 | "Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes" | | 38740993 | "Long-term weight loss effects of semaglutide in obesity without diabetes in the SELECT trial" | | 31422062 | "Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials" | | 39608381 | "Effects of GLP-1 receptor agonists on kidney and cardiovascular disease outcomes: a meta-analysis of randomised controlled trials" | | 35441470 | "Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension" | | 38937282 | "Changes in lean body mass with glucagon-like peptide-1-based therapies and mitigation strategies" | | 39719170 | "Effect of glucagon-like peptide-1 receptor agonists and co-agonists on body composition: Systematic review and network meta-analysis" | | 39996356 | "Body composition changes during weight reduction with tirzepatide in the SURMOUNT-1 study of adults with obesity or overweight" | | 39295512 | "Strategies for minimizing muscle loss during use of incretin-mimetic drugs for treatment of obesity" | | 40296814 | "Sarcopenic obesity and weight loss-induced muscle mass loss" | | 41549912 | "Micronutrient and Nutritional Deficiencies Associated With GLP-1 Receptor Agonist Therapy: A Narrative Review" | | 42419343 | "Nutritional, functional, and psychological considerations for incretin-based therapies in adults-an EASO, EFAD, and ECPO Consensus Statement" | | 39418085 | "Clinical Consequences of Delayed Gastric Emptying With GLP-1 Receptor Agonists and Tirzepatide" | | 39096914 | "Gastrointestinal effects of GLP-1 receptor agonists: mechanisms, management, and future directions" | | 38290907 | "Perioperative management of long-acting glucagon-like peptide-1 (GLP-1) receptor agonists: concerns for delayed gastric emptying and pulmonary aspiration" | | 26177483 | "Adverse Effects of GLP-1 Receptor Agonists" | | 36356111 | "GLP-1 Receptor Agonists and the Risk of Thyroid Cancer" | | 41998799 | "GLP-1 therapies and hair loss: A systematic review of current evidence and implications for counseling" | | 38741261 | "GLP-1 agonists and hair loss: a call for further investigation" | | 38952487 | "Clinical Pharmacokinetics of Semaglutide: A Systematic Review" |